Company: NIVFW
Filing Date: 2025-09-18
Form Type: F-1
Source: 0001213900-25-088927
Chunk: 23

Company: NewGenIvf Group Ltd
Filing Date: 2025-09-18
Form: F-1
Chunk 23
---
 indicated:

|                                         |     | For the Year ended December 31, |      2024 |     |   |       |     |     |      2023 |     |   |       |
|:----------------------------------------|:----|:--------------------------------|----------:|:----|:--|------:|:----|:----|----------:|:----|:--|------:|
|                                         |     | US$                             |           |     | % |       |     | US$ |           |     | % |       |
| IVF Treatment Service                   |     |                                 | 5,433,375 |     |   |   100 |     |     | 4,021,696 |     |   |  78.3 |
| Surrogacy and Ancillary Caring Services |     |                                 |         - |     |   |     0 |     |     | 1,114,457 |     |   |  21.7 |
| Total Revenue                           |     |                                 | 5,433,375 |     |   | 100.0 |     |     | 5,136,153 |     |   | 100.0 |

<div align='center'>8</div>

IVF Treatment Service

NewGenIvf primarily provides
its clients with conventional IVF/ICSI and embryo transfer services. NewGenIvf is also able to, through MicroSort technology, help fulfill
the family-balancing dreams of its clients and avoiding certain gender-related hereditary diseases.

IVF treatments that NewGenIvf
provides address tubal factor, ovulatory dysfunction, diminished ovarian reserve, endometriosis, uterine factor, male factor, unexplained
infertility and other causes. IVF bypasses the function of the fallopian tube by achieving fertilization within a laboratory environment.
Ovarian hyper-stimulation is common with IVF treatments to recruit numerous follicles to increase the chances for success. Follicles are
retrieved trans-vaginally using a vaginal probe and ultrasound guidance. Anaesthesia is frequently used due to the number of follicles
retrieved and the resulting discomfort experienced by the patient. The eggs are identified in the follicular fluid and combined with sperm
and culture medium in culture dishes, which are placed in an incubator with a temperature and gas environment designed to mimic the condition
of the fallopian tubes. Once the embryos develop, typically over a